Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Miriam Molina-Arcas"'
Autor:
Panayiotis Anastasiou, Christopher Moore, Sareena Rana, Mona Tomaschko, Claire E. Pillsbury, Andrea de Castro, Jesse Boumelha, Edurne Mugarza, Sophie de Carné Trécesson, Ania Mikolajczak, Cristina Blaj, Robert Goldstone, Jacqueline A. M. Smith, Elsa Quintana, Miriam Molina-Arcas, Julian Downward
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Mutant selective drugs targeting the inactive, GDP-bound form of KRASG12C have been approved for use in lung cancer, but resistance develops rapidly. Here we use an inhibitor, (RMC-4998) that targets RASG12C in its active, GTP-bound form, to
Externí odkaz:
https://doaj.org/article/f04ce583c0fc4b438b6298469e1bd117
Autor:
Julian Downward, Christopher Moore, Panayiotis Anastasiou, Sareena Rana, Jesse Boumelha, Mona Tomaschko, Miriam Molina-Arcas
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/461c8b07a5594e21aab3c20e8a16fe88
Autor:
Mohamed Ismail, Stephen R. Martin, Roger George, Francesca Houghton, Geoff Kelly, Raphaël A. G. Chaleil, Panayiotis Anastasiou, Xinyue Wang, Nicola O’Reilly, Stefania Federico, Dhira Joshi, Hemavathi Nagaraj, Rachel Cooley, Ning Sze Hui, Miriam Molina-Arcas, David C. Hancock, Ali Tavassoli, Julian Downward
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract P110α is a member of the phosphoinositide 3-kinase (PI3K) enzyme family that functions downstream of RAS. RAS proteins contribute to the activation of p110α by interacting directly with its RAS binding domain (RBD), resulting in the promot
Externí odkaz:
https://doaj.org/article/6034fbcb86144639966ed92b541f75ef
Autor:
Febe van Maldegem, Karishma Valand, Megan Cole, Harshil Patel, Mihaela Angelova, Sareena Rana, Emma Colliver, Katey Enfield, Nourdine Bah, Gavin Kelly, Victoria Siu Kwan Tsang, Edurne Mugarza, Christopher Moore, Philip Hobson, Dina Levi, Miriam Molina-Arcas, Charles Swanton, Julian Downward
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
The tumour microenvironment (TME) may change in response to cancer treatments such as KRAS G12C inhibition, with potential implications for combination therapies. Here, the authors provide an antibody panel and workflow for analysing the TME with ima
Externí odkaz:
https://doaj.org/article/c85c11c742864408a99b5e94e13e53db
Autor:
Sissy E. Wamaitha, Katarzyna J. Grybel, Gregorio Alanis-Lobato, Claudia Gerri, Sugako Ogushi, Afshan McCarthy, Shantha K. Mahadevaiah, Lyn Healy, Rebecca A. Lea, Miriam Molina-Arcas, Liani G. Devito, Kay Elder, Phil Snell, Leila Christie, Julian Downward, James M. A. Turner, Kathy K. Niakan
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
The signals regulating the establishment and maintenance of the pluripotent epiblast in human embryos are unclear. Here, the authors use a bioinformatics approach to identify the role of IGF1 in human embryo development, and from this, propose a cult
Externí odkaz:
https://doaj.org/article/104a33cb9a9247e1b51c23eb671ab8a2
Autor:
Greg G. Jones, Isabel Boned del Río, Sibel Sari, Aysen Sekerim, Lucy C. Young, Nicole Hartig, Itziar Areso Zubiaur, Mona A. El-Bahrawy, Rob E. Hynds, Winnie Lei, Miriam Molina-Arcas, Julian Downward, Pablo Rodriguez-Viciana
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
Targeted inhibition of the ERK-MAPK pathway is challenged by the development of resistance and toxicity. Here, the authors show that SHOC2 genetic inhibition impairs lung tumour development and improves MEK inhibitor efficacy in RAS- and EGFR-mutant
Externí odkaz:
https://doaj.org/article/63c728d50eef448aa2fdb9117a059704
Autor:
Jesse Boumelha, Sophie de Carné Trécesson, Emily K. Law, Pablo Romero-Clavijo, Matthew A. Coelho, Kevin W. Ng, Edurne Mugarza, Christopher Moore, Sareena Rana, Deborah R. Caswell, Miguel Murillo, David C. Hancock, Prokopios P. Argyris, William L. Brown, Cameron Durfee, Lindsay K. Larson, Rachel I. Vogel, Alejandro Suárez-Bonnet, Simon L. Priestnall, Philip East, Sarah J. Ross, George Kassiotis, Miriam Molina-Arcas, Charles Swanton, Reuben Harris, Julian Downward
Publikováno v:
Cancer Res
Mutations in oncogenes such as KRAS and EGFR cause a high proportion of lung cancers. Drugs targeting these proteins cause tumor regression but ultimately fail to elicit cures. As a result, there is an intense interest in how to best combine targeted
Autor:
Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Phil East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
Oncogenic KRAS impairs anti-tumour immune responses, but effective strategies to combine KRAS inhibitors and immunotherapies have so far proven elusive. In vivo CRISPR-Cas9 screening in an immunogenic murine lung cancer model identifies mechanisms by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c672d746fcfa1e56f0135765efec632
https://doi.org/10.1101/2023.04.13.536740
https://doi.org/10.1101/2023.04.13.536740
Supplementary Methods - PDF file 52K, Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61c39a76b0c19922c4addb2ddfba5873
https://doi.org/10.1158/2159-8290.22528661.v1
https://doi.org/10.1158/2159-8290.22528661.v1
Supplementary Figure 2 - PDF file 719K, Effects of MEK inhibitors on signal transduction pathways in NSCLC cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::798e32de0fdeae8615380f9b324c7be3
https://doi.org/10.1158/2159-8290.22528688
https://doi.org/10.1158/2159-8290.22528688